Table 3.
Effectiveness and safety outcomes before (registry sample) and after propensity score‐based standardized mortality ratio weighting (pseudotrial sample)
| Absolute PASI < 1.5 (~PASI 90) at 6 months | Incidence rate of SAEs per 1000 person‐years at 1 year | |
|---|---|---|
| Model 1 – Full registry cohort | ||
| Before weighting | 38.0 (36.6–39.5) | 75.0 (68.1–82.7) |
| After weighting | 37.1 (33.6–40.6) | 65.8 (51.6–83.7) |
| Absolute risk difference | 1.0 (−2.0–4.2) | 9.3 (−3.9–22.5) |
| Relative risk difference | 1.03 (0.94–1.11) | 1.14 (0.91–1.37) |
| Model 2 – Population with starting PASI ≥ 12 | ||
| Before weighting | 37.3 (35.4–39.3) | 79.8 (70.6–90.1) |
| After weighting | 38.6 (33.1–44.2) | 54.3 (42.8–69.0) |
| Absolute risk difference | −1.3 (−6.4–3.8) | 25.4 (14.0–37.0)a |
| Relative risk difference | 0.97 (0.84–1.09) | 1.47 (1.16–1.78)a |
| Model 3 – Population without any concomitant therapy during first year of therapy | ||
| Before weighting | 39.9 (38.2–41.6) | 73.5 (66.0–81.9) |
| After weighting | 38.5 (33.8–43.2) | 62.2 (48.3–79.9) |
| Absolute risk difference | 1.3 (−3.2–5.7) | 11.6 (−1.4–24.6) |
| Relative risk difference | 1.03 (0.91–1.15) | 1.18 (0.93–1.44) |
Data are the percentage proportion (95% confidence interval). PASI, Psoriasis Area and Severity Index; PASI 90, 90% improvement in PASI; SAE, serious adverse event. aStatistically significant result.